nodes	percent_of_prediction	percent_of_DWPC	metapath
Vilazodone—CYP2D6—Fingolimod—multiple sclerosis	0.184	0.261	CbGbCtD
Vilazodone—CYP3A4—Fingolimod—multiple sclerosis	0.117	0.166	CbGbCtD
Vilazodone—CYP3A4—Methylprednisolone—multiple sclerosis	0.0755	0.107	CbGbCtD
Vilazodone—CYP3A4—Triamcinolone—multiple sclerosis	0.0572	0.0811	CbGbCtD
Vilazodone—CYP3A4—Mitoxantrone—multiple sclerosis	0.0551	0.078	CbGbCtD
Vilazodone—CYP3A4—Betamethasone—multiple sclerosis	0.0491	0.0695	CbGbCtD
Vilazodone—CYP3A4—Prednisolone—multiple sclerosis	0.0484	0.0686	CbGbCtD
Vilazodone—CYP3A4—Prednisone—multiple sclerosis	0.0457	0.0648	CbGbCtD
Vilazodone—CYP2D6—Dexamethasone—multiple sclerosis	0.0449	0.0636	CbGbCtD
Vilazodone—CYP3A4—Dexamethasone—multiple sclerosis	0.0285	0.0405	CbGbCtD
Vilazodone—Gastroenteritis—Fingolimod—multiple sclerosis	0.00593	0.0244	CcSEcCtD
Vilazodone—Migraine—Fingolimod—multiple sclerosis	0.00517	0.0213	CcSEcCtD
Vilazodone—Connective tissue disorder—Fingolimod—multiple sclerosis	0.00357	0.0147	CcSEcCtD
Vilazodone—Eye disorder—Fingolimod—multiple sclerosis	0.0034	0.014	CcSEcCtD
Vilazodone—Cardiac disorder—Fingolimod—multiple sclerosis	0.00337	0.0139	CcSEcCtD
Vilazodone—Mental disorder—Fingolimod—multiple sclerosis	0.00319	0.0131	CcSEcCtD
Vilazodone—Vision blurred—Fingolimod—multiple sclerosis	0.00298	0.0123	CcSEcCtD
Vilazodone—Suicidal ideation—Methylprednisolone—multiple sclerosis	0.0029	0.0119	CcSEcCtD
Vilazodone—Palpitations—Fingolimod—multiple sclerosis	0.0028	0.0115	CcSEcCtD
Vilazodone—Mania—Methylprednisolone—multiple sclerosis	0.00279	0.0115	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Fingolimod—multiple sclerosis	0.00268	0.011	CcSEcCtD
Vilazodone—Suicidal ideation—Dexamethasone—multiple sclerosis	0.00263	0.0109	CcSEcCtD
Vilazodone—Suicidal ideation—Betamethasone—multiple sclerosis	0.00263	0.0109	CcSEcCtD
Vilazodone—Mania—Betamethasone—multiple sclerosis	0.00254	0.0105	CcSEcCtD
Vilazodone—Mania—Dexamethasone—multiple sclerosis	0.00254	0.0105	CcSEcCtD
Vilazodone—Nervous system disorder—Fingolimod—multiple sclerosis	0.00253	0.0104	CcSEcCtD
Vilazodone—Skin disorder—Fingolimod—multiple sclerosis	0.00251	0.0103	CcSEcCtD
Vilazodone—Paraesthesia—Fingolimod—multiple sclerosis	0.00232	0.00956	CcSEcCtD
Vilazodone—Suicidal ideation—Prednisone—multiple sclerosis	0.00229	0.00945	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Fingolimod—multiple sclerosis	0.00223	0.00919	CcSEcCtD
Vilazodone—Fatigue—Fingolimod—multiple sclerosis	0.00223	0.00918	CcSEcCtD
Vilazodone—Mania—Prednisone—multiple sclerosis	0.00221	0.00912	CcSEcCtD
Vilazodone—Cataract—Triamcinolone—multiple sclerosis	0.00214	0.00881	CcSEcCtD
Vilazodone—Connective tissue disorder—Cladribine—multiple sclerosis	0.00203	0.00835	CcSEcCtD
Vilazodone—Hyponatraemia—Mitoxantrone—multiple sclerosis	0.00197	0.0081	CcSEcCtD
Vilazodone—Cataract—Dexamethasone—multiple sclerosis	0.00194	0.008	CcSEcCtD
Vilazodone—Cataract—Betamethasone—multiple sclerosis	0.00194	0.008	CcSEcCtD
Vilazodone—Eye disorder—Cladribine—multiple sclerosis	0.00193	0.00794	CcSEcCtD
Vilazodone—Cardiac disorder—Cladribine—multiple sclerosis	0.00191	0.00788	CcSEcCtD
Vilazodone—Asthenia—Fingolimod—multiple sclerosis	0.00185	0.00764	CcSEcCtD
Vilazodone—Mental disorder—Cladribine—multiple sclerosis	0.00181	0.00744	CcSEcCtD
Vilazodone—Malnutrition—Cladribine—multiple sclerosis	0.00179	0.0074	CcSEcCtD
Vilazodone—Flatulence—Cladribine—multiple sclerosis	0.00177	0.00729	CcSEcCtD
Vilazodone—Diarrhoea—Fingolimod—multiple sclerosis	0.00177	0.00729	CcSEcCtD
Vilazodone—Increased appetite—Prednisolone—multiple sclerosis	0.00171	0.00705	CcSEcCtD
Vilazodone—Dizziness—Fingolimod—multiple sclerosis	0.00171	0.00704	CcSEcCtD
Vilazodone—Dry eye—Dexamethasone—multiple sclerosis	0.00171	0.00703	CcSEcCtD
Vilazodone—Dry eye—Betamethasone—multiple sclerosis	0.00171	0.00703	CcSEcCtD
Vilazodone—Cataract—Prednisone—multiple sclerosis	0.00169	0.00696	CcSEcCtD
Vilazodone—Increased appetite—Triamcinolone—multiple sclerosis	0.00157	0.00648	CcSEcCtD
Vilazodone—Increased appetite—Methylprednisolone—multiple sclerosis	0.00157	0.00647	CcSEcCtD
Vilazodone—Erectile dysfunction—Mitoxantrone—multiple sclerosis	0.00156	0.00643	CcSEcCtD
Vilazodone—Arthralgia—Cladribine—multiple sclerosis	0.00153	0.0063	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Cladribine—multiple sclerosis	0.00152	0.00625	CcSEcCtD
Vilazodone—Nervous system disorder—Cladribine—multiple sclerosis	0.00144	0.00592	CcSEcCtD
Vilazodone—Increased appetite—Dexamethasone—multiple sclerosis	0.00143	0.00588	CcSEcCtD
Vilazodone—Increased appetite—Betamethasone—multiple sclerosis	0.00143	0.00588	CcSEcCtD
Vilazodone—Skin disorder—Cladribine—multiple sclerosis	0.00142	0.00586	CcSEcCtD
Vilazodone—Hyperhidrosis—Cladribine—multiple sclerosis	0.00142	0.00583	CcSEcCtD
Vilazodone—Irritability—Methylprednisolone—multiple sclerosis	0.00141	0.0058	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Cladribine—multiple sclerosis	0.00133	0.0055	CcSEcCtD
Vilazodone—Breast disorder—Methylprednisolone—multiple sclerosis	0.00133	0.00549	CcSEcCtD
Vilazodone—Insomnia—Cladribine—multiple sclerosis	0.00132	0.00546	CcSEcCtD
Vilazodone—Migraine—Dexamethasone—multiple sclerosis	0.00132	0.00544	CcSEcCtD
Vilazodone—Migraine—Betamethasone—multiple sclerosis	0.00132	0.00544	CcSEcCtD
Vilazodone—Paraesthesia—Cladribine—multiple sclerosis	0.00131	0.00542	CcSEcCtD
Vilazodone—Somnolence—Cladribine—multiple sclerosis	0.0013	0.00537	CcSEcCtD
Vilazodone—Irritability—Betamethasone—multiple sclerosis	0.00128	0.00527	CcSEcCtD
Vilazodone—Irritability—Dexamethasone—multiple sclerosis	0.00128	0.00527	CcSEcCtD
Vilazodone—Decreased appetite—Cladribine—multiple sclerosis	0.00127	0.00525	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Cladribine—multiple sclerosis	0.00126	0.00521	CcSEcCtD
Vilazodone—Fatigue—Cladribine—multiple sclerosis	0.00126	0.0052	CcSEcCtD
Vilazodone—Increased appetite—Prednisone—multiple sclerosis	0.00124	0.00512	CcSEcCtD
Vilazodone—Arthralgia—Azathioprine—multiple sclerosis	0.00124	0.00512	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Azathioprine—multiple sclerosis	0.00123	0.00508	CcSEcCtD
Vilazodone—Feeling abnormal—Cladribine—multiple sclerosis	0.00121	0.00497	CcSEcCtD
Vilazodone—Skin disorder—Azathioprine—multiple sclerosis	0.00116	0.00477	CcSEcCtD
Vilazodone—Dysgeusia—Mitoxantrone—multiple sclerosis	0.00115	0.00476	CcSEcCtD
Vilazodone—Irritability—Prednisone—multiple sclerosis	0.00111	0.00459	CcSEcCtD
Vilazodone—Vision blurred—Mitoxantrone—multiple sclerosis	0.00111	0.00458	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Azathioprine—multiple sclerosis	0.00108	0.00447	CcSEcCtD
Vilazodone—Asthenia—Cladribine—multiple sclerosis	0.00105	0.00433	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Azathioprine—multiple sclerosis	0.00103	0.00424	CcSEcCtD
Vilazodone—Convulsion—Mitoxantrone—multiple sclerosis	0.00102	0.00421	CcSEcCtD
Vilazodone—Hallucination—Methylprednisolone—multiple sclerosis	0.00101	0.00418	CcSEcCtD
Vilazodone—Arthralgia—Mitoxantrone—multiple sclerosis	0.001	0.00414	CcSEcCtD
Vilazodone—Connective tissue disorder—Methylprednisolone—multiple sclerosis	0.001	0.00413	CcSEcCtD
Vilazodone—Diarrhoea—Cladribine—multiple sclerosis	0.001	0.00413	CcSEcCtD
Vilazodone—Feeling abnormal—Azathioprine—multiple sclerosis	0.000981	0.00404	CcSEcCtD
Vilazodone—Dizziness—Cladribine—multiple sclerosis	0.000968	0.00399	CcSEcCtD
Vilazodone—Eye disorder—Methylprednisolone—multiple sclerosis	0.000953	0.00393	CcSEcCtD
Vilazodone—Cardiac disorder—Methylprednisolone—multiple sclerosis	0.000946	0.0039	CcSEcCtD
Vilazodone—Skin disorder—Mitoxantrone—multiple sclerosis	0.000935	0.00385	CcSEcCtD
Vilazodone—Irritability—Methotrexate—multiple sclerosis	0.000931	0.00384	CcSEcCtD
Vilazodone—Vomiting—Cladribine—multiple sclerosis	0.000931	0.00384	CcSEcCtD
Vilazodone—Hyperhidrosis—Mitoxantrone—multiple sclerosis	0.00093	0.00384	CcSEcCtD
Vilazodone—Erectile dysfunction—Prednisone—multiple sclerosis	0.000929	0.00383	CcSEcCtD
Vilazodone—Hallucination—Dexamethasone—multiple sclerosis	0.000923	0.0038	CcSEcCtD
Vilazodone—Hallucination—Betamethasone—multiple sclerosis	0.000923	0.0038	CcSEcCtD
Vilazodone—Vision blurred—Prednisolone—multiple sclerosis	0.000912	0.00376	CcSEcCtD
Vilazodone—Mental disorder—Methylprednisolone—multiple sclerosis	0.000893	0.00368	CcSEcCtD
Vilazodone—Malnutrition—Methylprednisolone—multiple sclerosis	0.000888	0.00366	CcSEcCtD
Vilazodone—Breast disorder—Methotrexate—multiple sclerosis	0.000882	0.00363	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Mitoxantrone—multiple sclerosis	0.000877	0.00361	CcSEcCtD
Vilazodone—Dysgeusia—Triamcinolone—multiple sclerosis	0.000871	0.00359	CcSEcCtD
Vilazodone—Nausea—Cladribine—multiple sclerosis	0.00087	0.00359	CcSEcCtD
Vilazodone—Eye disorder—Dexamethasone—multiple sclerosis	0.000867	0.00357	CcSEcCtD
Vilazodone—Eye disorder—Betamethasone—multiple sclerosis	0.000867	0.00357	CcSEcCtD
Vilazodone—Paraesthesia—Mitoxantrone—multiple sclerosis	0.000864	0.00356	CcSEcCtD
Vilazodone—Somnolence—Mitoxantrone—multiple sclerosis	0.000856	0.00353	CcSEcCtD
Vilazodone—Dyspepsia—Mitoxantrone—multiple sclerosis	0.000847	0.00349	CcSEcCtD
Vilazodone—Convulsion—Prednisolone—multiple sclerosis	0.000838	0.00346	CcSEcCtD
Vilazodone—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000837	0.00345	CcSEcCtD
Vilazodone—Fatigue—Mitoxantrone—multiple sclerosis	0.00083	0.00342	CcSEcCtD
Vilazodone—Diarrhoea—Azathioprine—multiple sclerosis	0.000815	0.00336	CcSEcCtD
Vilazodone—Hallucination—Prednisone—multiple sclerosis	0.000804	0.00331	CcSEcCtD
Vilazodone—Connective tissue disorder—Prednisone—multiple sclerosis	0.000794	0.00327	CcSEcCtD
Vilazodone—Feeling abnormal—Mitoxantrone—multiple sclerosis	0.000793	0.00327	CcSEcCtD
Vilazodone—Dizziness—Azathioprine—multiple sclerosis	0.000787	0.00325	CcSEcCtD
Vilazodone—Erectile dysfunction—Methotrexate—multiple sclerosis	0.000777	0.0032	CcSEcCtD
Vilazodone—Convulsion—Triamcinolone—multiple sclerosis	0.000771	0.00318	CcSEcCtD
Vilazodone—Convulsion—Methylprednisolone—multiple sclerosis	0.000769	0.00317	CcSEcCtD
Vilazodone—Hyperhidrosis—Prednisolone—multiple sclerosis	0.000763	0.00315	CcSEcCtD
Vilazodone—Vomiting—Azathioprine—multiple sclerosis	0.000757	0.00312	CcSEcCtD
Vilazodone—Arthralgia—Methylprednisolone—multiple sclerosis	0.000756	0.00312	CcSEcCtD
Vilazodone—Eye disorder—Prednisone—multiple sclerosis	0.000755	0.00311	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Methylprednisolone—multiple sclerosis	0.000751	0.00309	CcSEcCtD
Vilazodone—Dry mouth—Triamcinolone—multiple sclerosis	0.000741	0.00305	CcSEcCtD
Vilazodone—Insomnia—Prednisolone—multiple sclerosis	0.000714	0.00294	CcSEcCtD
Vilazodone—Nervous system disorder—Methylprednisolone—multiple sclerosis	0.000711	0.00293	CcSEcCtD
Vilazodone—Paraesthesia—Prednisolone—multiple sclerosis	0.000709	0.00292	CcSEcCtD
Vilazodone—Mental disorder—Prednisone—multiple sclerosis	0.000708	0.00292	CcSEcCtD
Vilazodone—Nausea—Azathioprine—multiple sclerosis	0.000707	0.00292	CcSEcCtD
Vilazodone—Skin disorder—Methylprednisolone—multiple sclerosis	0.000704	0.0029	CcSEcCtD
Vilazodone—Malnutrition—Prednisone—multiple sclerosis	0.000703	0.0029	CcSEcCtD
Vilazodone—Hyperhidrosis—Triamcinolone—multiple sclerosis	0.000702	0.00289	CcSEcCtD
Vilazodone—Hyperhidrosis—Methylprednisolone—multiple sclerosis	0.0007	0.00289	CcSEcCtD
Vilazodone—Convulsion—Betamethasone—multiple sclerosis	0.000699	0.00288	CcSEcCtD
Vilazodone—Convulsion—Dexamethasone—multiple sclerosis	0.000699	0.00288	CcSEcCtD
Vilazodone—Asthenia—Mitoxantrone—multiple sclerosis	0.000691	0.00285	CcSEcCtD
Vilazodone—Vision blurred—Prednisone—multiple sclerosis	0.000663	0.00273	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Triamcinolone—multiple sclerosis	0.000662	0.00273	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Methylprednisolone—multiple sclerosis	0.00066	0.00272	CcSEcCtD
Vilazodone—Diarrhoea—Mitoxantrone—multiple sclerosis	0.000659	0.00271	CcSEcCtD
Vilazodone—Insomnia—Triamcinolone—multiple sclerosis	0.000657	0.00271	CcSEcCtD
Vilazodone—Insomnia—Methylprednisolone—multiple sclerosis	0.000655	0.0027	CcSEcCtD
Vilazodone—Paraesthesia—Triamcinolone—multiple sclerosis	0.000652	0.00269	CcSEcCtD
Vilazodone—Feeling abnormal—Prednisolone—multiple sclerosis	0.000651	0.00268	CcSEcCtD
Vilazodone—Paraesthesia—Methylprednisolone—multiple sclerosis	0.000651	0.00268	CcSEcCtD
Vilazodone—Nervous system disorder—Dexamethasone—multiple sclerosis	0.000646	0.00266	CcSEcCtD
Vilazodone—Nervous system disorder—Betamethasone—multiple sclerosis	0.000646	0.00266	CcSEcCtD
Vilazodone—Agitation—Prednisone—multiple sclerosis	0.000646	0.00266	CcSEcCtD
Vilazodone—Dyspepsia—Triamcinolone—multiple sclerosis	0.000639	0.00263	CcSEcCtD
Vilazodone—Dyspepsia—Methylprednisolone—multiple sclerosis	0.000638	0.00263	CcSEcCtD
Vilazodone—Hyperhidrosis—Betamethasone—multiple sclerosis	0.000637	0.00263	CcSEcCtD
Vilazodone—Hyperhidrosis—Dexamethasone—multiple sclerosis	0.000637	0.00263	CcSEcCtD
Vilazodone—Eye disorder—Methotrexate—multiple sclerosis	0.000631	0.0026	CcSEcCtD
Vilazodone—Cardiac disorder—Methotrexate—multiple sclerosis	0.000626	0.00258	CcSEcCtD
Vilazodone—Fatigue—Triamcinolone—multiple sclerosis	0.000626	0.00258	CcSEcCtD
Vilazodone—Fatigue—Methylprednisolone—multiple sclerosis	0.000625	0.00257	CcSEcCtD
Vilazodone—Vomiting—Mitoxantrone—multiple sclerosis	0.000612	0.00252	CcSEcCtD
Vilazodone—Convulsion—Prednisone—multiple sclerosis	0.000609	0.00251	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Dexamethasone—multiple sclerosis	0.0006	0.00247	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Betamethasone—multiple sclerosis	0.0006	0.00247	CcSEcCtD
Vilazodone—Arthralgia—Prednisone—multiple sclerosis	0.000599	0.00247	CcSEcCtD
Vilazodone—Feeling abnormal—Triamcinolone—multiple sclerosis	0.000598	0.00247	CcSEcCtD
Vilazodone—Feeling abnormal—Methylprednisolone—multiple sclerosis	0.000597	0.00246	CcSEcCtD
Vilazodone—Insomnia—Dexamethasone—multiple sclerosis	0.000596	0.00246	CcSEcCtD
Vilazodone—Insomnia—Betamethasone—multiple sclerosis	0.000596	0.00246	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—multiple sclerosis	0.000594	0.00245	CcSEcCtD
Vilazodone—Paraesthesia—Dexamethasone—multiple sclerosis	0.000592	0.00244	CcSEcCtD
Vilazodone—Paraesthesia—Betamethasone—multiple sclerosis	0.000592	0.00244	CcSEcCtD
Vilazodone—Mental disorder—Methotrexate—multiple sclerosis	0.000591	0.00244	CcSEcCtD
Vilazodone—Malnutrition—Methotrexate—multiple sclerosis	0.000588	0.00242	CcSEcCtD
Vilazodone—Dyspepsia—Dexamethasone—multiple sclerosis	0.00058	0.00239	CcSEcCtD
Vilazodone—Dyspepsia—Betamethasone—multiple sclerosis	0.00058	0.00239	CcSEcCtD
Vilazodone—Dysgeusia—Methotrexate—multiple sclerosis	0.000575	0.00237	CcSEcCtD
Vilazodone—Decreased appetite—Betamethasone—multiple sclerosis	0.000573	0.00236	CcSEcCtD
Vilazodone—Decreased appetite—Dexamethasone—multiple sclerosis	0.000573	0.00236	CcSEcCtD
Vilazodone—Nausea—Mitoxantrone—multiple sclerosis	0.000572	0.00236	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Dexamethasone—multiple sclerosis	0.000569	0.00234	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Betamethasone—multiple sclerosis	0.000569	0.00234	CcSEcCtD
Vilazodone—Fatigue—Betamethasone—multiple sclerosis	0.000568	0.00234	CcSEcCtD
Vilazodone—Fatigue—Dexamethasone—multiple sclerosis	0.000568	0.00234	CcSEcCtD
Vilazodone—Nervous system disorder—Prednisone—multiple sclerosis	0.000563	0.00232	CcSEcCtD
Vilazodone—Skin disorder—Prednisone—multiple sclerosis	0.000557	0.0023	CcSEcCtD
Vilazodone—Hyperhidrosis—Prednisone—multiple sclerosis	0.000555	0.00229	CcSEcCtD
Vilazodone—Vision blurred—Methotrexate—multiple sclerosis	0.000554	0.00228	CcSEcCtD
Vilazodone—Feeling abnormal—Betamethasone—multiple sclerosis	0.000543	0.00224	CcSEcCtD
Vilazodone—Feeling abnormal—Dexamethasone—multiple sclerosis	0.000543	0.00224	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Prednisone—multiple sclerosis	0.000523	0.00215	CcSEcCtD
Vilazodone—Dizziness—Prednisolone—multiple sclerosis	0.000522	0.00215	CcSEcCtD
Vilazodone—Asthenia—Triamcinolone—multiple sclerosis	0.000521	0.00215	CcSEcCtD
Vilazodone—Asthenia—Methylprednisolone—multiple sclerosis	0.00052	0.00214	CcSEcCtD
Vilazodone—Insomnia—Prednisone—multiple sclerosis	0.000519	0.00214	CcSEcCtD
Vilazodone—Paraesthesia—Prednisone—multiple sclerosis	0.000515	0.00212	CcSEcCtD
Vilazodone—Convulsion—Methotrexate—multiple sclerosis	0.000509	0.0021	CcSEcCtD
Vilazodone—Dyspepsia—Prednisone—multiple sclerosis	0.000505	0.00208	CcSEcCtD
Vilazodone—Arthralgia—Methotrexate—multiple sclerosis	0.0005	0.00206	CcSEcCtD
Vilazodone—Decreased appetite—Prednisone—multiple sclerosis	0.000499	0.00206	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—multiple sclerosis	0.000497	0.00205	CcSEcCtD
Vilazodone—Diarrhoea—Methylprednisolone—multiple sclerosis	0.000496	0.00204	CcSEcCtD
Vilazodone—Fatigue—Prednisone—multiple sclerosis	0.000495	0.00204	CcSEcCtD
Vilazodone—Dizziness—Triamcinolone—multiple sclerosis	0.00048	0.00198	CcSEcCtD
Vilazodone—Dizziness—Methylprednisolone—multiple sclerosis	0.000479	0.00197	CcSEcCtD
Vilazodone—Feeling abnormal—Prednisone—multiple sclerosis	0.000473	0.00195	CcSEcCtD
Vilazodone—Asthenia—Betamethasone—multiple sclerosis	0.000473	0.00195	CcSEcCtD
Vilazodone—Asthenia—Dexamethasone—multiple sclerosis	0.000473	0.00195	CcSEcCtD
Vilazodone—Nervous system disorder—Methotrexate—multiple sclerosis	0.00047	0.00194	CcSEcCtD
Vilazodone—Nausea—Prednisolone—multiple sclerosis	0.000469	0.00193	CcSEcCtD
Vilazodone—Skin disorder—Methotrexate—multiple sclerosis	0.000466	0.00192	CcSEcCtD
Vilazodone—Hyperhidrosis—Methotrexate—multiple sclerosis	0.000464	0.00191	CcSEcCtD
Vilazodone—Vomiting—Triamcinolone—multiple sclerosis	0.000462	0.0019	CcSEcCtD
Vilazodone—Vomiting—Methylprednisolone—multiple sclerosis	0.000461	0.0019	CcSEcCtD
Vilazodone—Diarrhoea—Betamethasone—multiple sclerosis	0.000451	0.00186	CcSEcCtD
Vilazodone—Diarrhoea—Dexamethasone—multiple sclerosis	0.000451	0.00186	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Methotrexate—multiple sclerosis	0.000437	0.0018	CcSEcCtD
Vilazodone—Dizziness—Dexamethasone—multiple sclerosis	0.000436	0.0018	CcSEcCtD
Vilazodone—Dizziness—Betamethasone—multiple sclerosis	0.000436	0.0018	CcSEcCtD
Vilazodone—Insomnia—Methotrexate—multiple sclerosis	0.000434	0.00179	CcSEcCtD
Vilazodone—Nausea—Triamcinolone—multiple sclerosis	0.000431	0.00178	CcSEcCtD
Vilazodone—Paraesthesia—Methotrexate—multiple sclerosis	0.000431	0.00177	CcSEcCtD
Vilazodone—Nausea—Methylprednisolone—multiple sclerosis	0.00043	0.00177	CcSEcCtD
Vilazodone—Somnolence—Methotrexate—multiple sclerosis	0.000426	0.00176	CcSEcCtD
Vilazodone—Dyspepsia—Methotrexate—multiple sclerosis	0.000422	0.00174	CcSEcCtD
Vilazodone—Vomiting—Dexamethasone—multiple sclerosis	0.000419	0.00173	CcSEcCtD
Vilazodone—Vomiting—Betamethasone—multiple sclerosis	0.000419	0.00173	CcSEcCtD
Vilazodone—Decreased appetite—Methotrexate—multiple sclerosis	0.000417	0.00172	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Methotrexate—multiple sclerosis	0.000414	0.00171	CcSEcCtD
Vilazodone—Fatigue—Methotrexate—multiple sclerosis	0.000413	0.0017	CcSEcCtD
Vilazodone—Asthenia—Prednisone—multiple sclerosis	0.000412	0.0017	CcSEcCtD
Vilazodone—Feeling abnormal—Methotrexate—multiple sclerosis	0.000395	0.00163	CcSEcCtD
Vilazodone—Diarrhoea—Prednisone—multiple sclerosis	0.000393	0.00162	CcSEcCtD
Vilazodone—Nausea—Dexamethasone—multiple sclerosis	0.000391	0.00161	CcSEcCtD
Vilazodone—Nausea—Betamethasone—multiple sclerosis	0.000391	0.00161	CcSEcCtD
Vilazodone—Dizziness—Prednisone—multiple sclerosis	0.000379	0.00156	CcSEcCtD
Vilazodone—Vomiting—Prednisone—multiple sclerosis	0.000365	0.0015	CcSEcCtD
Vilazodone—Asthenia—Methotrexate—multiple sclerosis	0.000344	0.00142	CcSEcCtD
Vilazodone—Nausea—Prednisone—multiple sclerosis	0.000341	0.0014	CcSEcCtD
Vilazodone—Diarrhoea—Methotrexate—multiple sclerosis	0.000328	0.00135	CcSEcCtD
Vilazodone—Dizziness—Methotrexate—multiple sclerosis	0.000317	0.00131	CcSEcCtD
Vilazodone—Vomiting—Methotrexate—multiple sclerosis	0.000305	0.00126	CcSEcCtD
Vilazodone—Nausea—Methotrexate—multiple sclerosis	0.000285	0.00117	CcSEcCtD
Vilazodone—HTR1A—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	0.000168	0.00325	CbGpPWpGaD
Vilazodone—CYP2C18—Biological oxidations—POMC—multiple sclerosis	0.000165	0.00319	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—CYP27B1—multiple sclerosis	0.000164	0.00317	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—CYP24A1—multiple sclerosis	0.000164	0.00317	CbGpPWpGaD
Vilazodone—HTR1A—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	0.000162	0.00314	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000161	0.00312	CbGpPWpGaD
Vilazodone—CYP3A4—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000161	0.00312	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CCR1—multiple sclerosis	0.00016	0.00309	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CXCL13—multiple sclerosis	0.00016	0.00309	CbGpPWpGaD
Vilazodone—HTR1A—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	0.000158	0.00305	CbGpPWpGaD
Vilazodone—HTR1A—G alpha (i) signalling events—CNR1—multiple sclerosis	0.000157	0.00304	CbGpPWpGaD
Vilazodone—DRD2—G alpha (i) signalling events—CXCR3—multiple sclerosis	0.000153	0.00297	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—GPR65—multiple sclerosis	0.000153	0.00297	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.000149	0.00289	CbGpPWpGaD
Vilazodone—DRD2—G alpha (i) signalling events—CCR2—multiple sclerosis	0.000149	0.00289	CbGpPWpGaD
Vilazodone—DRD2—GPCRs, Class A Rhodopsin-like—PTGER4—multiple sclerosis	0.000147	0.00285	CbGpPWpGaD
Vilazodone—HTR1A—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	0.000146	0.00282	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.000144	0.00278	CbGpPWpGaD
Vilazodone—DRD2—GPCRs, Class A Rhodopsin-like—CXCR3—multiple sclerosis	0.000142	0.00276	CbGpPWpGaD
Vilazodone—HTR1A—G alpha (i) signalling events—CXCL10—multiple sclerosis	0.000141	0.00273	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CXCL13—multiple sclerosis	0.00014	0.00271	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CCR1—multiple sclerosis	0.00014	0.00271	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.000139	0.00269	CbGpPWpGaD
Vilazodone—DRD2—GPCRs, Class A Rhodopsin-like—CCR2—multiple sclerosis	0.000138	0.00268	CbGpPWpGaD
Vilazodone—DRD2—G alpha (i) signalling events—CNR1—multiple sclerosis	0.000138	0.00267	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.000135	0.00262	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL3—multiple sclerosis	0.000131	0.00254	CbGpPWpGaD
Vilazodone—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000131	0.00253	CbGpPWpGaD
Vilazodone—DRD2—GPCRs, Class A Rhodopsin-like—CNR1—multiple sclerosis	0.000128	0.00247	CbGpPWpGaD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	0.000127	0.00245	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—PTGER4—multiple sclerosis	0.000126	0.00244	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CYP27B1—multiple sclerosis	0.000125	0.00242	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—CYP24A1—multiple sclerosis	0.000125	0.00242	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.000125	0.00241	CbGpPWpGaD
Vilazodone—DRD2—G alpha (i) signalling events—CXCL10—multiple sclerosis	0.000124	0.0024	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—S1PR1—multiple sclerosis	0.000122	0.00237	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCR3—multiple sclerosis	0.000122	0.00236	CbGpPWpGaD
Vilazodone—HTR1A—G alpha (i) signalling events—CCL5—multiple sclerosis	0.000122	0.00235	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR2—multiple sclerosis	0.000119	0.0023	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—GPC5—multiple sclerosis	0.000114	0.00222	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CCL3—multiple sclerosis	0.000114	0.0022	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	0.000112	0.00217	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—S1PR1—multiple sclerosis	0.000111	0.00215	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—PTGER4—multiple sclerosis	0.00011	0.00212	CbGpPWpGaD
Vilazodone—HTR1A—G alpha (i) signalling events—CCR5—multiple sclerosis	0.00011	0.00212	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—CNR1—multiple sclerosis	0.000109	0.00212	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—FAS—multiple sclerosis	0.000108	0.00209	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—S1PR1—multiple sclerosis	0.000107	0.00208	CbGpPWpGaD
Vilazodone—DRD2—G alpha (i) signalling events—CCL5—multiple sclerosis	0.000107	0.00207	CbGpPWpGaD
Vilazodone—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000106	0.00205	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CXCR3—multiple sclerosis	0.000106	0.00205	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—RGS1—multiple sclerosis	0.000104	0.00201	CbGpPWpGaD
Vilazodone—SLC6A4—NRF2 pathway—TGFB1—multiple sclerosis	0.000104	0.00201	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CCR2—multiple sclerosis	0.000103	0.00199	CbGpPWpGaD
Vilazodone—HTR1A—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	0.000102	0.00197	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CCL3—multiple sclerosis	9.99e-05	0.00193	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—GPR65—multiple sclerosis	9.87e-05	0.00191	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL10—multiple sclerosis	9.86e-05	0.00191	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—S1PR1—multiple sclerosis	9.76e-05	0.00189	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	9.67e-05	0.00187	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—PTGER4—multiple sclerosis	9.62e-05	0.00186	CbGpPWpGaD
Vilazodone—DRD2—G alpha (i) signalling events—CCR5—multiple sclerosis	9.62e-05	0.00186	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CNR1—multiple sclerosis	9.5e-05	0.00184	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—RRM1—multiple sclerosis	9.49e-05	0.00184	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—RGS1—multiple sclerosis	9.45e-05	0.00183	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CXCR3—multiple sclerosis	9.29e-05	0.0018	CbGpPWpGaD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—TNF—multiple sclerosis	9.18e-05	0.00178	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—RGS1—multiple sclerosis	9.14e-05	0.00177	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CCR2—multiple sclerosis	9.03e-05	0.00175	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CCR1—multiple sclerosis	9.02e-05	0.00175	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CXCL13—multiple sclerosis	9.02e-05	0.00175	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—GPR65—multiple sclerosis	8.96e-05	0.00173	CbGpPWpGaD
Vilazodone—DRD2—GPCRs, Class A Rhodopsin-like—CCR5—multiple sclerosis	8.92e-05	0.00173	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—IL1B—multiple sclerosis	8.82e-05	0.00171	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	8.71e-05	0.00169	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—LINGO1—multiple sclerosis	8.66e-05	0.00168	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—GPR65—multiple sclerosis	8.66e-05	0.00168	CbGpPWpGaD
Vilazodone—HTR1A—G alpha (i) signalling events—POMC—multiple sclerosis	8.56e-05	0.00166	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CXCL10—multiple sclerosis	8.55e-05	0.00165	CbGpPWpGaD
Vilazodone—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	8.54e-05	0.00165	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL5—multiple sclerosis	8.49e-05	0.00164	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CNR1—multiple sclerosis	8.34e-05	0.00161	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—RGS1—multiple sclerosis	8.3e-05	0.00161	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CCR1—multiple sclerosis	8.19e-05	0.00159	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CXCL13—multiple sclerosis	8.19e-05	0.00159	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CXCL13—multiple sclerosis	7.92e-05	0.00153	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CCR1—multiple sclerosis	7.92e-05	0.00153	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—GPR65—multiple sclerosis	7.87e-05	0.00152	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—CCR5—multiple sclerosis	7.65e-05	0.00148	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—LINGO1—multiple sclerosis	7.61e-05	0.00147	CbGpPWpGaD
Vilazodone—DRD2—G alpha (i) signalling events—POMC—multiple sclerosis	7.51e-05	0.00145	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TAGAP—multiple sclerosis	7.51e-05	0.00145	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CXCL10—multiple sclerosis	7.51e-05	0.00145	CbGpPWpGaD
Vilazodone—SLC6A4—SIDS Susceptibility Pathways—IL6—multiple sclerosis	7.41e-05	0.00143	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CCL5—multiple sclerosis	7.36e-05	0.00142	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CXCL13—multiple sclerosis	7.2e-05	0.00139	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CCR1—multiple sclerosis	7.2e-05	0.00139	CbGpPWpGaD
Vilazodone—CYP3A4—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	6.93e-05	0.00134	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	6.81e-05	0.00132	CbGpPWpGaD
Vilazodone—HTR1A—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	6.66e-05	0.00129	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CCR5—multiple sclerosis	6.63e-05	0.00128	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TAGAP—multiple sclerosis	6.6e-05	0.00128	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—S1PR1—multiple sclerosis	6.57e-05	0.00127	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CCL5—multiple sclerosis	6.46e-05	0.00125	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—TNF—multiple sclerosis	6.4e-05	0.00124	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—GPC5—multiple sclerosis	6.39e-05	0.00124	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PTGER4—multiple sclerosis	6.19e-05	0.0012	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SRM—multiple sclerosis	6.07e-05	0.00118	CbGpPWpGaD
Vilazodone—SLC6A4—Circadian rythm related genes—IL6—multiple sclerosis	6.05e-05	0.00117	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CXCR3—multiple sclerosis	5.98e-05	0.00116	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—POMC—multiple sclerosis	5.98e-05	0.00116	CbGpPWpGaD
Vilazodone—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL2—multiple sclerosis	5.85e-05	0.00113	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CCL3—multiple sclerosis	5.84e-05	0.00113	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CCR5—multiple sclerosis	5.82e-05	0.00113	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CCR2—multiple sclerosis	5.82e-05	0.00113	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—S1PR1—multiple sclerosis	5.77e-05	0.00112	CbGpPWpGaD
Vilazodone—CYP2D6—Biological oxidations—POMC—multiple sclerosis	5.63e-05	0.00109	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PTGER4—multiple sclerosis	5.62e-05	0.00109	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—GPC5—multiple sclerosis	5.61e-05	0.00109	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—RGS1—multiple sclerosis	5.58e-05	0.00108	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—BCHE—multiple sclerosis	5.45e-05	0.00105	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PTGER4—multiple sclerosis	5.43e-05	0.00105	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CXCR3—multiple sclerosis	5.43e-05	0.00105	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CNR1—multiple sclerosis	5.37e-05	0.00104	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—GPR65—multiple sclerosis	5.29e-05	0.00102	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CCR2—multiple sclerosis	5.28e-05	0.00102	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CXCR3—multiple sclerosis	5.25e-05	0.00102	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—POMC—multiple sclerosis	5.18e-05	0.001	CbGpPWpGaD
Vilazodone—HTR1A—SIDS Susceptibility Pathways—IL6—multiple sclerosis	5.16e-05	0.000999	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CCL3—multiple sclerosis	5.13e-05	0.000992	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CCR2—multiple sclerosis	5.11e-05	0.000988	CbGpPWpGaD
Vilazodone—HTR1A—GPCR ligand binding—CCL2—multiple sclerosis	5.07e-05	0.000981	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PTGER4—multiple sclerosis	4.93e-05	0.000955	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—RGS1—multiple sclerosis	4.9e-05	0.000949	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CNR1—multiple sclerosis	4.87e-05	0.000943	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CXCL13—multiple sclerosis	4.84e-05	0.000937	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCR1—multiple sclerosis	4.84e-05	0.000937	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CXCL10—multiple sclerosis	4.83e-05	0.000935	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CXCR3—multiple sclerosis	4.77e-05	0.000922	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CNR1—multiple sclerosis	4.71e-05	0.000912	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—GPR65—multiple sclerosis	4.65e-05	0.000899	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CCR2—multiple sclerosis	4.64e-05	0.000897	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—POMC—multiple sclerosis	4.55e-05	0.000881	CbGpPWpGaD
Vilazodone—DRD2—GPCR ligand binding—CCL2—multiple sclerosis	4.45e-05	0.000862	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CXCL10—multiple sclerosis	4.39e-05	0.000849	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CNR1—multiple sclerosis	4.28e-05	0.000828	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	4.28e-05	0.000828	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	4.28e-05	0.000828	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCR1—multiple sclerosis	4.25e-05	0.000823	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CXCL13—multiple sclerosis	4.25e-05	0.000823	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CXCL10—multiple sclerosis	4.24e-05	0.000821	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CCL5—multiple sclerosis	4.16e-05	0.000805	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SRM—multiple sclerosis	3.97e-05	0.000768	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GPC5—multiple sclerosis	3.91e-05	0.000757	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CXCL10—multiple sclerosis	3.85e-05	0.000746	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CCL5—multiple sclerosis	3.78e-05	0.000731	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—CCR5—multiple sclerosis	3.75e-05	0.000725	CbGpPWpGaD
Vilazodone—DRD2—Circadian rythm related genes—IL6—multiple sclerosis	3.7e-05	0.000716	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—IL2RA—multiple sclerosis	3.69e-05	0.000715	CbGpPWpGaD
Vilazodone—CYP3A4—Biological oxidations—POMC—multiple sclerosis	3.68e-05	0.000712	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CCL5—multiple sclerosis	3.65e-05	0.000707	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCL3—multiple sclerosis	3.45e-05	0.000668	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CCR5—multiple sclerosis	3.4e-05	0.000659	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—IL2RA—multiple sclerosis	3.35e-05	0.000649	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PTGER4—multiple sclerosis	3.32e-05	0.000643	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CCL5—multiple sclerosis	3.32e-05	0.000642	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—CCR5—multiple sclerosis	3.29e-05	0.000637	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—APOE—multiple sclerosis	3.28e-05	0.000634	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PGR—multiple sclerosis	3.27e-05	0.000633	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—IL2RA—multiple sclerosis	3.24e-05	0.000628	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—RRM1—multiple sclerosis	3.24e-05	0.000627	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CXCR3—multiple sclerosis	3.21e-05	0.000621	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CD28—multiple sclerosis	3.18e-05	0.000615	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCR2—multiple sclerosis	3.12e-05	0.000604	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCL3—multiple sclerosis	3.03e-05	0.000586	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CCR5—multiple sclerosis	2.99e-05	0.000578	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—IL2RA—multiple sclerosis	2.94e-05	0.00057	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—POMC—multiple sclerosis	2.93e-05	0.000567	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PTGER4—multiple sclerosis	2.92e-05	0.000564	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CNR1—multiple sclerosis	2.88e-05	0.000557	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PGR—multiple sclerosis	2.87e-05	0.000556	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—POMC—multiple sclerosis	2.82e-05	0.000545	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CXCR3—multiple sclerosis	2.82e-05	0.000545	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP27B1—multiple sclerosis	2.8e-05	0.000541	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP24A1—multiple sclerosis	2.8e-05	0.000541	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CD28—multiple sclerosis	2.79e-05	0.00054	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCR2—multiple sclerosis	2.74e-05	0.00053	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—POMC—multiple sclerosis	2.66e-05	0.000515	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CCL2—multiple sclerosis	2.6e-05	0.000504	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CXCL10—multiple sclerosis	2.59e-05	0.000502	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—POMC—multiple sclerosis	2.57e-05	0.000498	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ALB—multiple sclerosis	2.57e-05	0.000497	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GPC5—multiple sclerosis	2.56e-05	0.000495	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CNR1—multiple sclerosis	2.53e-05	0.000489	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—TYK2—multiple sclerosis	2.36e-05	0.000457	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—POMC—multiple sclerosis	2.34e-05	0.000452	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CCL2—multiple sclerosis	2.28e-05	0.000442	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CXCL10—multiple sclerosis	2.28e-05	0.00044	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CD86—multiple sclerosis	2.27e-05	0.000439	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCL5—multiple sclerosis	2.23e-05	0.000432	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—IL2—multiple sclerosis	2.17e-05	0.000419	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—RRM1—multiple sclerosis	2.12e-05	0.00041	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—TYK2—multiple sclerosis	2.07e-05	0.000402	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SPP1—multiple sclerosis	2.07e-05	0.0004	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCR5—multiple sclerosis	2.01e-05	0.000389	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CD86—multiple sclerosis	1.99e-05	0.000385	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IL2RA—multiple sclerosis	1.98e-05	0.000383	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—IL2—multiple sclerosis	1.97e-05	0.000381	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCL5—multiple sclerosis	1.96e-05	0.000379	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—IL2—multiple sclerosis	1.9e-05	0.000368	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—BCHE—multiple sclerosis	1.86e-05	0.00036	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—APOE—multiple sclerosis	1.83e-05	0.000354	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SPP1—multiple sclerosis	1.81e-05	0.000351	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCR5—multiple sclerosis	1.76e-05	0.000342	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IL2RA—multiple sclerosis	1.74e-05	0.000337	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—IL2—multiple sclerosis	1.73e-05	0.000334	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CD80—multiple sclerosis	1.65e-05	0.00032	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—APOE—multiple sclerosis	1.61e-05	0.000311	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—POMC—multiple sclerosis	1.57e-05	0.000304	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCL2—multiple sclerosis	1.54e-05	0.000298	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—MAPK1—multiple sclerosis	1.5e-05	0.000291	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CD80—multiple sclerosis	1.45e-05	0.000281	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TYK2—multiple sclerosis	1.4e-05	0.00027	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—POMC—multiple sclerosis	1.38e-05	0.000267	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCL2—multiple sclerosis	1.35e-05	0.000261	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—MAPK1—multiple sclerosis	1.32e-05	0.000256	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TYK2—multiple sclerosis	1.23e-05	0.000237	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—BCHE—multiple sclerosis	1.22e-05	0.000236	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IL2—multiple sclerosis	1.16e-05	0.000225	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—IL6—multiple sclerosis	1.16e-05	0.000224	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—APOE—multiple sclerosis	1.12e-05	0.000217	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MMP9—multiple sclerosis	1.1e-05	0.000213	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IL2—multiple sclerosis	1.02e-05	0.000197	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—IL6—multiple sclerosis	1.01e-05	0.000196	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—STAT3—multiple sclerosis	9.77e-06	0.000189	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MMP9—multiple sclerosis	9.65e-06	0.000187	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—POMC—multiple sclerosis	9.62e-06	0.000186	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MYC—multiple sclerosis	9.08e-06	0.000176	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TGFB1—multiple sclerosis	9.06e-06	0.000175	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MAPK1—multiple sclerosis	8.88e-06	0.000172	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ALB—multiple sclerosis	8.77e-06	0.00017	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—STAT3—multiple sclerosis	8.58e-06	0.000166	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MYC—multiple sclerosis	7.97e-06	0.000154	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TGFB1—multiple sclerosis	7.95e-06	0.000154	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MAPK1—multiple sclerosis	7.8e-06	0.000151	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—APOE—multiple sclerosis	7.32e-06	0.000142	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IL6—multiple sclerosis	6.83e-06	0.000132	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—POMC—multiple sclerosis	6.29e-06	0.000122	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IL6—multiple sclerosis	5.99e-06	0.000116	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ALB—multiple sclerosis	5.74e-06	0.000111	CbGpPWpGaD
